Blog
RSS FeedPosted by Michael Wonder on 02 Mar 2024
Patisiran sodium in hereditary transthyretin amyloidosis: less benefit than vutrisiran
1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study. ...
Posted by Michael Wonder on 01 Feb 2024
Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy
1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...
Posted by Michael Wonder on 18 Jan 2024
New orphan drug for a sub-type of acute myeloid leukaemia: G-BA sees significant additional benefit
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
Posted by Michael Wonder on 04 Dec 2023
Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...
Posted by Michael Wonder on 15 Nov 2023
Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...
Posted by Michael Wonder on 09 Oct 2023
Multiple sclerosis: hardly any evidence for good patient care
4 October 2023 - Even in the final report, many questions about the treatment of relapsing-remitting multiple sclerosis remain unanswered because ...
Posted by Michael Wonder on 08 Oct 2023
Clinical studies: you can see better with the second arm
6 October 2023 - In a statement to the EMA, the IQWiG emphasised that single-arm studies may be sufficient for ...
Posted by Michael Wonder on 05 Oct 2023
Orphan drug for multiple myeloma: G-BA must formally certify legally assumed additional benefit
5 October 2023 - Due to legal requirements, the Federal Joint Committee (G-BA) has completed the re-evaluation process for belantamab mafodotin ...
Posted by Michael Wonder on 19 Sep 2023
How IQWiG assesses – version 7.0 of the method paper comes into force
19 September 2023 - Fundamental revision of the cost benefit assessment and addition of the concept of application-accompanying data collection. ...
Posted by Michael Wonder on 02 Sep 2023
Lisocabtagene maraleucel in second-line B-cell lymphoma: additional benefit for certain patients
1 September 2023 - On the basis of the available data, there is a hint of a non-quantifiable added benefit ...
Posted by Michael Wonder on 02 Aug 2023
Upadacitinib in active Crohn's disease: no additional benefit proven due to a lack of comparative studies
1 August 2023 - Although biologics have been used in Crohn's disease for over 20 years, there are hardly any studies ...
Posted by Michael Wonder on 27 Jul 2023
Access and availability: Why are Europeans finding it hard to get the new medicines they need?
27 July 2023 - Patients are struggling to get hold of the new medicines they desperately need and ask what ...
Posted by Michael Wonder on 25 Jul 2023
"Last hope": Eager Germans are prepared to pay for weight loss drug
25 July 2023 - Frustrated after countless failed diet and exercise attempts, 41 year old Jessica Lenth from Hamburg has ...
Posted by Michael Wonder on 06 Jul 2023
Extension of indications in drug approval: often without proof of additional benefit
6 July 2023 - In a comment in the BMJ, the head of the IQWiG Department for drug assessment advocates approval ...
Posted by Michael Wonder on 03 Jul 2023
EU-HTA: G-BA coordinates parallel scientific consultations for manufacturers from September
3 July 2023 - From 2025, a systematic evaluation of clinical studies for new medicinal products and medical devices will ...